Supraspacular nerve block reduced chronic shoulder pain and disability in degenerative disease or rheumatoid arthritis


Clinical impact ratings GP/FP/Primary care ★★★★★★ Rheumatology ★★★★★★★

In patients with chronic shoulder pain from degenerative disease or rheumatoid arthritis, is suprascapular nerve block (SNB) effective for reducing the resulting pain and disability?

**METHODS**

**Design**: randomised placebo controlled trial.

**Allocation**: concealed.*

**Blinding**: patients and outcome assessors.*

**Follow up period**: 12 weeks.

**Setting**: St Vincent’s University Hospital in Dublin, Ireland and the Repatriation Hospital in Adelaide, South Australia.

**Patients**: 83 unslected patients (108 shoulders) (mean age 73 y, 52% men) with chronic shoulder pain of >3 months’ duration resulting from degenerative disease (43 patients, 56 shoulders) or rheumatoid arthritis (40 patients, 52 shoulders). Exclusion criteria included a known allergy to the injecting agents, severe chronic airways disease, cardiac failure, and adhesive capsulitis.

**Intervention**: shoulders were allocated to SNB (n = 56) or placebo (n = 52). SNB consisted of an injection into the supraspacular fossa of a combination of bupivacaine (10 ml of a 0.5% solution) and methylprednisolone (1 ml containing 40 mg) after local analgesia with lidocaine (2 ml of a 1% solution). The placebo injection consisted of normal saline (5 ml) infiltrated subcutaneously after local analgesia with lidocaine (2 ml of a 1% solution).

**Outcomes**: shoulder pain and disability (0–100 shoulder pain and disability index [SPADI]) measured at baseline, and at weeks 1, 4, and 12 of follow up.

**Patient follow up**: shoulder follow up was 94%.

*See glossary.

**MAIN RESULTS**

Analysis was by intention to treat. Improvement in shoulder pain and disability and the number of shoulders that improved by >10 points on the SPADI scale were greater in the SNB group than in the placebo group throughout follow up (table).

**CONCLUSION**

Supraspacular nerve block was effective for reducing chronic shoulder pain and disability in patients with degenerative disease or rheumatoid arthritis.

**Commentary**

The trial by Shanahan et al showed convincing pain relief lasting for >12 weeks after SNB with bupivacaine and methylprednisolone. The results are generalisable to patients who are referred to secondary care with chronic shoulder pain arising from damaged joints (91% of shoulders were abnormal on x-ray). A more modest improvement in shoulder related disability was observed, which reflects the degree to which pain (as opposed to mechanical factors) affects function. This technique is especially useful when the shoulder joint or rotator cuff is substantially damaged because concern exists that repeated intra-articular steroid injections in this setting may increase the rate of structural decline. On the other hand, an intra-articular steroid injection in the context of joint inflammation may have a positive influence on the underlying pathology. The 2 techniques cannot, therefore, be viewed as straightforward alternatives.

It is notable that previous studies have shown the benefit of SNB with bupivacaine alone in rheumatoid arthritis and frozen shoulder, whereas this trial used a combination of bupivacaine and methylprednisolone. Little information exists in the literature on the longer term outcome of SNB or the benefit of repeated intra-articular steroid injections.

Deborah Symmons, MD, FRCP
University of Manchester Medical School
Manchester, UK


For correspondence: Dr M Shanahan, Repatriation General Hospital, Daw Park, South Australia, Australia. michael.shanahan@rgh.sa.gov.au

Sources of funding: National Health and Medical Research Council of Australia and the Arthritis Foundation of Australia.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Mean improvement from baseline in shoulder pain and disability (SPADI total scores 0–100)</th>
<th><strong>Follow up</strong></th>
<th><strong>SNB</strong></th>
<th><strong>Placebo</strong></th>
<th><strong>Difference between groups (95% CI)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>Week 1</strong></td>
<td>17</td>
<td>0.66</td>
<td>16 (9.9 to 22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Week 4</strong></td>
<td>14</td>
<td>0.80</td>
<td>13 (6.6 to 19)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Week 12</strong></td>
<td>14</td>
<td>2.6</td>
<td>11 (3.6 to 18)</td>
</tr>
<tr>
<td></td>
<td><strong>RBI (CI)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NNT (CI)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of shoulders that improved by &gt;10 SPADI total scores</td>
<td><strong>Follow up</strong></td>
<td><strong>Week 1</strong></td>
<td>67%</td>
<td>24%</td>
<td>186% (74 to 393)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Week 4</strong></td>
<td>65%</td>
<td>11%</td>
<td>501% (175 to 1309)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Week 12</strong></td>
<td>55%</td>
<td>19%</td>
<td>192% (60 to 459)</td>
</tr>
</tbody>
</table>

*SPADI = shoulder pain and disability index. Other abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article.

†NNT refers to number of shoulders needed to treat.
Suprascapular nerve block reduced chronic shoulder pain and disability in degenerative disease or rheumatoid arthritis

Evid Based Med 2004 9: 50
doi: 10.1136/ebm.9.2.50

Updated information and services can be found at:
http://ebm.bmj.com/content/9/2/50

These include:

References
This article cites 3 articles, 2 of which you can access for free at:
http://ebm.bmj.com/content/9/2/50#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Pain (neurology) (413)
- Degenerative joint disease (110)
- Musculoskeletal syndromes (219)
- Pain (anaesthesia) (75)
- Interventional cardiology (150)
- Pain (palliative care) (98)
- Connective tissue disease (44)
- Immunology (including allergy) (571)
- Rheumatoid arthritis (29)
- Clinical trials (epidemiology) (1596)
- Drugs: cardiovascular system (754)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/